A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

Exclusion Criteria

• •1. Received prior anticancer or other investigational therapy within 28 days or 5× the half-life prior to the first dose.
• •2. Prior treatment with ripretinib.
• •3. Patients who have had prior repaglinide treatment within 14 days prior to Cycle 1 Day 1.
• •4. History or presence of clinically relevant cardiovascular abnormalities.
• •5. Gastrointestinal abnormalities including but not limited to:
• •* inability to take oral medication,
• •* malabsorption syndromes,
• •* requirement for intravenous alimentation.
• •6. Patients who have type 1 or type 2 diabetes.